Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$119.79 USD
+1.35 (1.14%)
Updated Oct 31, 2025 03:59 PM ET
After-Market: $119.74 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Gilead Sciences, Inc. has a PEG ratio of 0.80 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GILD 119.79 +1.35(1.14%)
Will GILD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GILD
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Other News for GILD
Gilead price target raised to $145 from $127 at Truist
Gilead price target raised by $18 at Truist, here's why
Is GILD likely to continue higher? Crossed Above 20 Day Moving Average shows up after advancing 1.14%
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?